Interleukin-12 - Opportunities for the treatment of bladder cancer
Interleukin-12 - Opportunities for the treatment of bladder cancer
复制标题
DOI：
10.1016/s0094-0143(05)70242-1
复制
发表时间：
2000-02-01
影响因子：
2.4
通讯作者：
O'Donnell, MA
中科院分区：
文献类型：
--
作者：
Clinton, SK;Canto, E;O'Donnell, MA
尽管对人类免疫系统的了解还不完全，但肿瘤免疫学的快速进展为不久的将来有效和安全的干预提供了框架。癌症患者的早期治疗方法集中于干扰素和IL-12对免疫系统的非特异性和广泛刺激，将被靶向精确定义的肿瘤抗原的免疫反应的高度特异性刺激所取代。IL-12具有几种生物学特性，似乎可用于膀胱癌的免疫治疗。在膀胱癌的临床前动物模型中，IL-12的显著抗肿瘤反应提供了乐观的前景，即未来涉及该药物的临床试验可能会影响与该疾病相关的风险和死亡率。
Despite incomplete understanding of the human immune system, the rapid progress in tumor immunology provides a framework for effective and safe interventions in the near future. Early approaches in patients with cancer that have focused on the nonspecific and broad stimulation of the immune system by interferons and IL-12 will be replaced by the highly specific stimulation of immune reactions targeting precisely defined tumor antigens. IL-12 has several biologic properties that seem useful in immune therapy fur bladder cancer. The striking antitumor responses with IL-12 in preclinical animal models of bladder cancer provide optimism that future clinical trials involving this agent may impact on the risk and mortality associated with this disease.